BioSpace News Archive

Drug Development

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.

November 28, 2023
·
5 min read
Job Trends

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration RoslinCT will manufacture world’s-first CRISPR-based therapy.

November 28, 2023
·
4 min read
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value creation.

November 28, 2023
·
5 min read
Business

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

Korro Bio, Inc. today announced the appointment of Rachel Meyers, PhD, to the Company’s Board of Directors.

November 28, 2023
·
2 min read
Biotech Beach

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

BioAtla, Inc. today announced it will host a virtual KOL Event on Monday, December 4, 2023 at 11:00 AM ET.

November 28, 2023
·
6 min read
Biotech Beach

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Erasca, Inc. announced program updates for pan-RAF inhibitor naporafenib and central nervous system -penetrant EGFR inhibitor ERAS-801, as well as a strategic program prioritization that extends its projected cash runway from H2 2025 to H1 2026.

November 28, 2023
·
9 min read
Genetown

Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 5, 2023 at 11:00 a.m. ET.

November 28, 2023
·
1 min read
Business

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors.

November 28, 2023
·
6 min read
Pharm Country

KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023

KORU Medical Systems, Inc. today announced it will host an investor day at the Mahwah, NJ headquarters on Tuesday, December 5, 2023, from 10:00 a.m. to 12:00 p.m. Eastern Time.

November 28, 2023
·
1 min read
Genetown

Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences

Thermo Fisher Scientific Inc., the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis.

November 28, 2023
·
3 min read